DnB Asset Management
CRL icon

DnB Asset Management’s Charles River Laboratories CRL Stock Holding History

DnB Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Sell
2,723
-148
-5% -$26.4K ﹤0.01% 724
2026
Q1 		$495K Buy
+2,871
New +$532K ﹤0.01% 769
2025
Q1 		– Sell
-8,690
Closed -$1.6M – 749
2024
Q4 		$1.6M Buy
8,690
+124
+1% +$23.9K 0.01% 613
2024
Q3 		$1.69M Buy
8,566
+183
+2% +$38K 0.01% 599
2024
Q2 		$1.73M Buy
8,383
+1,196
+17% +$271K 0.01% 582
2024
Q1 		$1.95M Buy
+7,187
New +$1.72M 0.01% 537

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

DnB Asset Management's CRL Position: Q2 2026 in Review

DnB Asset Management reduced its Charles River Laboratories (CRL) stake by 5.2% in Q2 2026, selling an estimated $26.4K and leaving 2,723 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #724.

DnB Asset Management first reported a position in CRL in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.95M in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • DnB Asset Management held 2,723 shares of Charles River Laboratories worth $618K as of Q2 2026.
  • DnB Asset Management sold 148 Charles River Laboratories shares in Q2 2026, an estimated $26.4K.
  • Charles River Laboratories made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #724 holding.
  • DnB Asset Management first reported a position in Charles River Laboratories in Q1 2024 and has held it in 6 quarters since.
  • DnB Asset Management's Charles River Laboratories position peaked at $1.95M in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.